|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest earning deposits in banks | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Debt securities available for sale at fair value | ||||||||||||||||||||
| Held to maturity securities at amortized cost | ||||||||||||||||||||
| Total securities | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Gross loans held for investment | ||||||||||||||||||||
| Unearned income, net | ||||||||||||||||||||
| Loans held for investment, net of unearned income | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Total loans held for investment, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Foreclosed assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Noninterest bearing deposits | ||||||||||||||||||||
| Interest bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Preferred stock, no par value; authorized 500,000 shares; no shares issued and outstanding | ||||||||||||||||||||
| Common stock, $1.00 par value; authorized 30,000,000 shares; issued shares of 21,580,067 and 21,580,067; outstanding shares of 20,632,760 and 20,777,485 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock at cost, 947,307 and 802,582 shares | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...
